Words by Jade Williams
In an effort to bolster its biomanufacturing capacity, Amgen is investing $1bn to build a second drug substance manufacturing facility in Holly Springs, North Carolina. This expansion increases the company’s total planned investment in the region to more than $1.5bn, following an earlier commitment of $550m.
“This expansion underscores our unwavering focus on bringing transformative medicines to patients around the world,” said Robert A. Bradway, Chairman and Chief Executive Officer, Amgen. “North Carolina will be an important part of our global manufacturing network as we continue to meet the growing demand for our innovative therapies while generating significant local economic impact.”
The new facility will utilise advanced manufacturing technologies and sustainable practices and will generate 370 new jobs, further solidifying North Carolina’s position as a biomanufacturing hub for Amgen.
Roy Cooper, North Carolina Governor, welcomed the announcement, highlighting its significance for the state’s biotechnology sector. "North Carolina's reputation as one of the world's leading centers for biotechnology soars even higher with today's decision by Amgen," said Cooper. “North Carolina offers everything an innovative biotech company needs to succeed, especially our highly trained, dedicated and diverse workforce, which is fine-tuned to the needs of this critical industry.”
This expansion will strengthen Amgen's global manufacturing footprint and enable the continued delivery of its medicines for cancer, heart disease, osteoporosis, inflammation and rare diseases.
